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ABSTRACT
The identification of tumor-specific antigens and the immune responses directed 
against them has instigated the development of therapies to enhance antitumor 
immune responses. Most of these cancer immunotherapies are administered 
systemically rather than directly to tumors. Nonetheless, numerous studies 
have demonstrated that intratumoral therapy is an attractive approach, both for 
immunization and immunomodulation purposes. Injection, recruitment and/or 
activation of antigen-presenting cells in the tumor nest have been extensively studied 
as strategies to cross-prime immune responses. Moreover, delivery of stimulatory 
cytokines, blockade of inhibitory cytokines and immune checkpoint blockade have 
been explored to restore immunological fitness at the tumor site. These tumor-
targeted therapies have the potential to induce systemic immunity without the toxicity 
that is often associated with systemic treatments. We review the most promising 
intratumoral immunotherapies, how these affect systemic antitumor immunity such 
that disseminated tumor cells are eliminated, and which approaches have been proven 
successful in animal models and patients.
INTRODUCTION
Cancer immunotherapy, instructing the immune 
system to recognize and kill cancer cells, is a strategy 
that can result in systemic and selective destruction of 
tumor cells as well as the formation of memory responses 
capable of counteracting recurring disease. This concept 
originated in the beginning of the 20th century when Paul 
Ehrlich formulated his “immune surveillance hypothesis”. 
Herein it is postulated that foreign invaders can be 
recognized and selectively eliminated by the immune 
system [1]. Over half a century later, Burnet and Thomas, 
extended this hypothesis to include cancer cells. In their 
“tumor surveillance hypothesis”, it is proposed that cancer 
cells are recognized as “foreign” by the immune system 
[2]. This hypothesis implies that cancer cells can be 
specifically eliminated without damaging the healthy cells 
they arise from, in a similar way to virally infected cells. 
The identification of antigens that are specifically 
or preferentially expressed by cancer cells but not by 
normal tissues offered a rationale for this hypothesis. 
These antigens are collectively known as tumor associated 
antigens and are subdivided into several groups according 
to their expression pattern. The most important classes 
are cancer-testis antigens, differentiation antigens, 
viral antigens, mutated antigens and antigens that are 
over expressed in tumors. Of these, only viral antigens, 
such as the human papilloma virus E6/E7 proteins and 
antigens derived from the mutanome are genuinely tumor-
specific and foreign to the immune system. All other 
tumor antigens are considered “self”. Therefore several 
tolerogenic mechanisms have to be conquered to induce 
a productive antitumor immune response. Nonetheless, 
it has been shown that tumor antigens, like cancer-testis 
antigens, give rise to a number of epitopes. These can be 
presented in MHC class I or class II molecules to the T-cell 
receptor of CD8+ or CD4+ T cells respectively. When this 
functional recognition coincides with strong stimulatory 
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signals, the CD8+ and CD4+ T cells are driven towards 
cytotoxic T lymphocytes (CTLs) and T helper type 1 (TH1) 
cells respectively. Attempts to stimulate immunity against 
tumor antigens and consequently against the entire tumor 
have been undertaken based on the extensive research on 
the immunogenicity of these antigens [3]. 
Most cancer immunotherapies are administered 
systemically rather than directly into tumors, despite the 
pioneering work of William B. Coley, who demonstrated 
that heat-inactivated bacterial cultures from Streptococci 
and Serratia marcescens could induce tumor regression, 
and that the therapy outcome was most favorable when 
these bacteria were injected in the proximity of the tumor 
[4]. The growing knowledge on tumor immunology 
provides a rationale for Coley’s findings. In response to 
tumor-mediated factors, infiltrating immune cells like 
dendritic cells (DCs), natural killer (NK) cells and CTLs 
are suppressed, whilst other cell types, such as myeloid-
derived suppressor cells (MDSCs), tumor-associated 
macrophages (TAMs) and regulatory T cells (Tregs), are 
exploited to the tumor’s advantage (Fig. 1). Importantly, 
tumor-resident antigen-presenting cells, such as DCs that 
carry tumor antigens, can become activated by pathogen-
associated molecular patterns (PAMPs). Consequently, 
they escape the immunosuppressive tumor environment 
and migrate to the tumor-draining lymph nodes where 
they can prime T cells. Despite the fact that cross-priming 
of tumor-specific T cells is a critical step in anticancer 
immunotherapy, it does not automatically imply tumor 
regression. This is explained by the presence of numerous 
T-cell suppressive factors within the tumor nest. Therefore, 
therapies that modulate key suppressive factors are equally 
important as strategies that drive T-cell stimulation. 
However, the immune system has still its mysteries, as 
for instance immunosuppressive drugs such as rapamycin 
and rapalogs (rapamycin-like compounds) can be used for 
cancer prevention and therapy [5–7]. Therefore, careful 
analysis of which compounds will be manipulated in the 
immune system need to be taken into account. 
This review provides a comprehensive summary 
of the state-of-the-art on intratumoral immunotherapies, 
including both stimulation and immunomodulation 
approaches.
Figure 1: Schematic representation of tumor environment; interactions between tumor and immune cells. Different 
immune cell types mediate the destruction of tumor cells such as NK and T cells. In contrast to the direct effects exerted by NK cells, 
adaptive T-cell responses are generated once DCs have primed T cells in the draining lymph nodes. However, the tumor modifies the 
environment in order to disrupt these antitumor effects and recruits and stimulates suppressive immune cells. Abbreviations: CTL (Cytotoxic 
T Lymphocytes); DC (Dendritic Cell); MDSC (Myeloid-Derived Suppressor Cell); NK cell (Natural Killer cell); TAA (Tumor-Associated 
Antigen); TAM (Tumor-Associaded Macrophages); TDLN (Tumor-Draining Lymph Nodes); Treg (Regulatory T cells).
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INTRATUMORAL IMMUNIZATION
Intratumoral injection of dendritic cells
The era of DC vaccination was unleashed by the 
pioneering work of Inaba et al. [8], who showed that 
mouse DCs could be cultured ex vivo from bone marrow 
cells. In 2011, Ralph Steinman received the Nobel Prize 
for the discovery of this cell type and its role in adaptive 
immunity. The primary objective of DC-based antitumor 
vaccination is to achieve stimulation of long-lived 
cancer-specific T-cell responses. For this purpose, ex vivo 
generated DCs are typically loaded with tumor antigens 
and simultaneously or subsequently matured [9].
Much debate exists on the optimal way to generate 
and mature DCs ex vivo and on the possible clinical failure 
due to suboptimal DC maturation. A detailed description 
on the generation of DC vaccines is provided in [9, 10]. 
Another important matter concerns the choice of antigens 
and the delivery platform. The latter has been examined in 
detail elsewhere [11, 12]. Even supposing that an ideal mix 
of antigens is found, a recurrent issue is the simultaneous 
evolvement of tumors and their antigens. The loss of 
antigens is a mechanism that is exploited by tumor cells 
to escape antitumor immune responses [13]. Therefore, 
loading of DCs with “classical” tumor antigens might in 
part explain why only a temporary control of tumors is 
observed in many experimental settings. 
To circumvent these issues, delivery of “empty” DCs 
to the tumor has been explored. This idea is based on the 
presumption that the DCs will capture antigens released 
by the tumor and drain to lymphoid organs to present their 
cargo to T cells. This concept was evaluated by Hirao et 
al. [14], who showed that ex vivo generated mouse DCs 
can migrate from the tumor to draining lymph nodes and 
cross-prime tumor-specific TH1-responses. However, 
analysis of the migration of intratumorally injected human 
DCs showed that most of them remain inside the tumor. 
It was found that tumors from hepatocellular carcinoma, 
colorectal or pancreatic cancer patients produced IL-
8; a chemokine that attracts DCs and that blocks their 
migration towards MIP-3β (CCL19), a cytokine that draws 
DCs to lymphoid organs [15]. Of note, mice do not express 
a homologue for human IL-8, therefore the retention of 
DCs due to IL-8 production cannot be investigated in mice 
[16]. Nonetheless, the approach of delivering DCs into the 
tumor has been further explored.
Since activation of TH1 cells and CTLs requires 
strong co-stimulation, the “next generation intratumoral 
DC-based vaccines” were composed of DCs modified to 
express high levels of T-cell promoting cytokines either 
or not combined with co-stimulatory molecules [17]. An 
example of such experimental setting is the use of DCs 
modified to express IL-12; a heterodimeric cytokine with 
various immune promoting functions. Nishioka et al. [18] 
demonstrated that bone marrow-derived DCs that were 
retrovirally transduced to express high levels of IL-12, 
were able to evoke antitumor immune responses capable 
of mediating regression of established tumors, including 
the weakly immunogenic B16 melanoma. This result could 
not be obtained when delivering non-transduced DCs or 
IL-12 producing fibroblasts, indicating the need for both 
IL-12 and potent antigen-presenting cells. Satoh et al. [19] 
confirmed these findings showing therapeutic antitumor 
immune responses in a model of colorectal cancer upon 
delivery of DCs that were modified with adenoviral 
vectors harboring the IL-12 gene. However, it must be 
acknowledged that although the effects were attributed 
to the presence of IL-12, the viral vectors used in these 
studies have the ability to induce DC maturation [20, 21]. 
Since it was shown in mice with metastatic prostate cancer 
that intratumoral immunization with DCs over-expressing 
both IL-12 and the co-stimulatory molecule B7.1 (CD80) 
resulted in less lung metastases than immunization with 
DCs expressing only IL-12 [22], it cannot be excluded 
that other maturation-inducing factors contributed to the 
outcome observed in the Nishioka [18] and Satoh [19] 
study. 
To further improve immunization upon intratumoral 
delivery of DCs, several research groups have combined 
the expression of IL-12 with other cytokines, including 
IL-18 [23], or IL-21 and IFN-α [24]. These studies 
showed that DCs modified to produce multiple stimulatory 
cytokines were more efficient in stimulating therapeutic 
T-cell responses than DCs producing only IL-12. 
The use of monocyte-derived DCs modified with 
adenoviral vectors harboring the IL-12 gene was translated 
to the clinic by the group of Ignacio Melero [17]. 
Seventeen patients were treated in a pilot study; 3, 5 and 
9 of whom suffered from metastatic pancreatic, colorectal 
or primary liver malignancies respectively. These patients 
received 3 intratumoral injections of DCs at escalating 
doses at a 21-day interval. The most common side 
effects were lymphopenia, fever and malaise. Antibodies 
against adenoviral components were also detected. As 
these hamper repeated injection of the vaccine, they are 
also considered as adverse events. Importantly, immune 
reactions were observed in these patients: elevated IFN-α 
and IL-6 serum levels were detected in 15 patients, 
increase in NK cell activity was observed in 5 patients 
and 3 patients showed presence of tumor-infiltrating CD8+ 
T cells. Moreover, a partial response was observed in 1 
patient with pancreatic carcinoma, whereas stabilization of 
the disease was observed in 2 patients. This study showed 
that delivery of IL-12 producing DCs to the tumor is 
feasible and well tolerated but further improvements are 
required to increase clinical efficacy. 
Taken together, the pre-clinical and clinical 
studies described above suggest that DCs delivered to 
the tumor are able to ingest tumor antigens, which can 
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then be presented to effector immune cells. Moreover, 
modifications of DCs to secrete cytokines can further 
enhance the efficacy of this approach. 
Intratumoral injection of cytokines to recruit 
dendritic cells
The direct injection of ex vivo generated DCs 
is a straightforward strategy to ensure an increase of 
DC numbers in the tumor environment. However, the 
generation of DCs ex vivo is costly, laborious and time-
consuming. In addition, it is known that DCs are a 
heterogeneous population of antigen-presenting cells; 
several DC-subsets, endowed with distinct functions, 
have been described in mice and men [25]. It is currently 
unclear, which DC-subset is most suitable for vaccination. 
In addition, it remains a major challenge to generate high 
numbers of DCs that resemble a certain subset of in vivo 
existing cells [26]. Therefore, recruiting DCs directly in 
vivo offers an attractive alternative.
Several strategies have been employed to attract DCs 
to the tumor. They typically depend on delivery of growth 
factors, such as Flt3L and GM-CSF [27–29]. Both factors 
have been intensively studied for the in vitro generation 
of DCs, and data showed that Flt3L-derived DCs share 
morphological characteristics and surface antigens with 
normal lymphoid-derived DC-subsets activated with LPS 
or IFN-α [30]. In contrast, DCs cultured in GM-CSF 
express myeloid cell surface antigens such as CD11c and 
lack the expression of CD8α; therefore they are considered 
to be the progeny of cells of the myeloid lineage [8]. 
In vivo Flt3/Flt3L-mediated signaling regulates the 
generation and differentiation of plasmacytoid, resident 
and migratory DCs from bone marrow progenitor cells 
[31, 32]. In earlier days subcutaneous injection of Flt3L 
in tumor bearing mice has been used as a strategy to 
increase DC numbers and mediate tumor control [33, 34]. 
However, the intratumoral delivery of Flt3L has shown 
variable outcome. It was shown in a hepatoma, colorectal 
cancer (SMCC-1) and breast cancer model that adenoviral 
delivery of Flt3L to the tumor resulted in an increase 
in DCs and tumor-specific T cells, and as such delayed 
tumor growth [35, 36]. Combining the delivery of Flt3L 
with the induction of tumor cell apoptosis enhanced the 
therapeutic effect. In contrast, Riediger et al. [37] failed 
to show the therapeutic potential of adenoviral delivery 
of Flt3L in CT26 colorectal tumors. The latter might be 
due to differences in immunogenicity between the SMCC-
1 and CT26 colorectal tumor models. Importantly, this 
highlights the risk of extrapolating data from one model 
to the other. 
The application of GM-CSF as a cytokine to attract 
immature DCs to the tumor was first demonstrated by 
Pan et al. [38]. Using a model of hepatic metastatic colon 
cancer they showed that intratumoral delivery of GM-
CSF resulted in the recruitment of DCs as well as the 
capture of antigens and subsequent maturation of these 
DCs. This in turn enabled them to migrate to lymphoid 
tissues, where they were able to activate antigen-specific 
T cells. Moreover, intratumoral delivery of plasmid DNA 
encoding GM-CSF resulted in an increased number of 
immature DCs [39]. However, this was not enough to 
induce effective antitumor activity; it was hypothesized 
that GM-CSF lead to expansion of the already infiltrated 
(and functionally impaired) DCs. Only co-delivery 
of CCL20 (MIP-3α) with GM-CSF resulted in tumor 
antigen (MUC1)-specific antitumor immune responses. 
Therefore, it was suggested that CCL20 was responsible 
for the recruitment of novel functional DCs to the tumor 
and that GM-CSF triggered the subsequent expansion and 
maturation of the recruited cells [40, 41]. 
It is known that DCs within the tumor environment 
are under the influence of a plethora of inhibitory 
mechanisms, which impairs their maturation process. It 
has been proposed that strong adjuvants can jumpstart 
the activation program in DCs. In this regard, Davis et al. 
[42] have combined the use of GM-CSF with the delivery 
of LPS, a strong activator of the pattern recognition 
receptor (PRR) TLR4, achieving an increase in the 
number of activated antigen-presenting cells in the tumor 
environment. They showed in several tumor models, 
including the melanoma model B16 and the colorectal 
model CT26, that this treatment strategy leads to an 
overall decrease in tumor volume. 
GM-CSF has also been delivered by oncolytic 
viruses (Herpes simplex virus-1, HSV-1) to lesions of 
patients with metastatic melanoma [43, 44]. This strategy 
was well tolerated and melanoma lesions treated with 
these viruses exhibited a higher number of MART-1-
specific T cells, whilst showed a reduction in Tregs and 
MDSCs. More importantly, a 26% objective response 
rate and 1-year survival rate of 58% was observed for 
all patients. The duration of the response was between 
16 and 40 months. It is hypothesized that this approach 
takes advantage of the induction of tumor cell death and 
attraction of DCs. Tumor cell death generates phagocytic 
material for antigen-presenting cells [45] and provides 
damage-associated molecular patterns (DAMPs) that are 
able to activate DCs. These DAMPs include uric acid, heat 
shock proteins, adenosine triphosphate and high mobility 
group box 1 proteins [46–49]. Immune activation upon 
induction of virus-mediated tumor cell death was even 
reported in the absence of these DAMPs, suggesting that 
viral components might suffice for an activation of the 
tumor-infiltrating DCs [14, 50, 51]. 
In conclusion, these studies reveal that DCs might 
be attracted to the tumor using different growth factors. 
In addition, they suggest that DC recruitment is a first 
step that needs to be followed by antigen loading and 
subsequent DC activation to induce potent antitumor 
immune responses. 
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Intratumoral delivery of dendritic cell 
potentiating factors
Professional antigen-presenting cells actively 
infiltrate tumor lesions. However, these cells are subjected 
to immunosuppressive mechanisms, which inhibit them 
to perform properly. Two main DC potentiating strategies 
will be reviewed in this section: triggering of TLRs and 
CD40. Additionally, we will discuss a number of co-
stimulatory molecules that have been used to enhance 
T-cell mediated responses.
Intratumoral delivery of TLR agonists
TLRs are members of the PRR family of which 
the genetic sequence is widely conserved over distant 
organisms. Until now, 13 TLRs have been characterized 
in mammals, of which 10 are also found in humans [52]. 
A broad range of PAMPs and DAMPs is recognized by 
different TLRs. Notably, the function of TLRs is not 
restricted to innate immune responses as initially thought; 
TLRs also play a role in tissue repair and in adaptive 
DC and T cell-mediated immune responses against 
cancer [53]. Interestingly, the very first immunotherapy 
approaches applied by Busch, Coley and others were in 
fact taking advantage of the activation of the immune 
system through these TLRs [52, 54].
Growing evidence suggest that the delivery of TLR-
agonists into the tumor nest (locally) is preferred over its 
systemic administration. Besides an improved outcome, 
this strategy decreases the side effects related to systemic 
TLR-agonist administration, such as the induction of 
uncontrolled and overwhelming inflammation [55]. 
An important issue when using TLR-agonists for 
intratumoral delivery is related to the choice of the best-
suited agonist for DC activation and thus for the induction 
of antitumor immunity. Of note, distinct DC subsets are 
shown to preferentially express certain TLRs [56, 57]. This 
differential TLR expression pattern reflects the functional 
specialization of DC populations, which depending on the 
nature of an invader can direct the appropriate immune 
response.
Amongst all TLRs, TLR4 is the best characterized. 
TLR4 is strongly activated by LPS; its systemic 
administration leads to a massive release of pro-
inflammatory cytokines and as a result so-called endotoxic 
shock. However, combining DC mobilization with TLR4-
triggering was efficacious for the treatment of different 
murine tumor models [42, 58]. Therapeutic potential of 
intratumoral administration of immature DCs with topical 
application of a TLR7 agonist (Imiquimod) was also 
demonstrated in a mouse melanoma model [59]. The effect 
of Imiquimod seems to depend on local administration, 
since its systemic delivery was previously shown to be 
ineffective for the treatment of human carcinomas [60]. 
The use of TLR7 agonists without additional delivery 
of DCs to the tumor was also investigated in a murine 
breast cancer model, showing that TLR7-triggering on 
infiltrating plasmacytoid DCs resulted in their activation. 
This activation lead to high expression of type I IFNs, 
which contributed to the therapeutic effect observed in 
this model [61]. 
The immune activating capacity of CpG-ODN, a 
TLR9 agonist, upon intratumoral delivery was illustrated 
by Shirota et al. [62], who showed that monocytic MDSCs 
lost their suppressive activity upon TLR9 triggering 
and acquired a tumoricidal phenotype. Of note, this 
group previously reported that these effects were not 
obtained upon systemic administration of CpG-ODN 
[62]. Remarkably, several phase I clinical trials in which 
CpG-ODN was delivered to the tumor to treat malignant 
melanoma yielded promising results. Hofmann et al. [63] 
achieved tumor regression in half of the treated subjects 
using this strategy, whereas Molenkamp et al. [64] and 
Brody et al. [65] showed that CpG-ODN administration, 
either alone or combined with radiotherapy induced tumor 
regression, accompanied by the generation of tumor-
specific CD8+ T cells. 
Two recent studies report on the effect of 
intratumoral administration of CpG-ODN and polyI:C, 
a potent TLR3 ligand, and their ability to convert the 
chronic inflammatory tumor environment into an acute 
inflammatory environment. This was shown to rescue 
the functionality of CD8+ T cells that were adoptively 
transferred or generated through vaccination [66, 67]. 
Increased efficacy of the applied immunotherapeutic 
approach in these studies was linked to the activation 
of tumor-infiltrating DCs, as characterized by the 
enhanced expression of co-stimulatory molecules and 
pro-inflammatory cytokines. These data show that the 
administration of TLR agonists such as polyI:C, LPS, 
imiquimod and CpG-ODN, has therapeutic anticancer 
potential. However, it needs to be clarified which agonist 
has the best curative profile. Only a few studies addressed 
this question; Shirota et al. [62] evaluated whether 
triggering of TLR2, 3, 4 and 8 on MDSCs had a similar 
effect as described for the stimulation of TLR7 and 
TLR9, including the differentiation of the MDSCs to a 
tumoricidal, macrophage-resembling phenotype. Although 
MDSCs express TLR2, 3, 4 and 8, triggering of these 
TLRs did not result in MDSC-differentiation. Intratumoral 
delivery of CpG-ODN in the murine glioma model GL261 
inhibited tumor growth in vivo and cured 80% of the 
mice [68]. Subsequently, they demonstrated increased 
frequencies of tumor-infiltrating IFN-α producing effector 
T cells and a marked increase in the ratio of CD4+ effector 
T cells to CD4+ Foxp3+ Tregs. They evidenced in this 
study that only intratumoral injection of CpG-ODN, 
Pam3Cys-SK4 or R848 stimulating TLR9, 1/2 and 7/8 
respectively, leads to survival benefit, whereas stimulation 
of TLR3 or 4 by injection of poly(I:C) or LPS alone is 
not effective. This comparative study highlights that TLR-
agonists that might be successful in one model might not 
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necessarily be effective in another [68]. This might have 
several explanations; the work of Shirota et al. [62] on 
MDSCs and their phenotype after stimulation with various 
TLR-ligands, suggests that the composition of immune 
infiltrate might play an important role. It is also known 
that tumor cells themselves express various TLRs and 
their stimulation leads to a different effect than triggering 
of the same TLRs on immune cells. For instance, it has 
been shown that intratumoral administration of LPS can 
induce resistance to CTLs and drives NK cell anergy [69], 
whereas triggering of TLR3 on certain tumor cell types 
results in tumor growth arrest [70]. Therefore, triggering 
of TLRs can be considered a double edged sword, as it 
can also be protumoral [71]. This is highlighted by the 
fact that in some cases triggering of TLRs on cancerous 
cells can result in promotion of tumor growth, evasion 
and chemoresistance [69, 72–74]. Additionally, signaling 
upon TLR-activation is tightly regulated; this control 
includes several negative activation loops, which have 
been reviewed in detail elsewhere [75, 76]. The presence 
of soluble decoy receptors like soluble TLR2 and TLR4 
and the down-regulation of TLR expression by anti-
inflammatory cytokines, such as TGF-β and IL-10 are 
the most likely functional mechanisms in the tumor 
environment. Delivery of constitutively active TLRs 
(caTLRs) to immune cells using viral or non-viral methods 
allows evaluation of their performance on immune cells, 
whilst circumventing the inhibitory mechanisms. These 
caTLRs and their use for DC-activation, have been 
reviewed by Breckpot et al. [53]. Our group observed 
that intratumoral administration of mRNA encoding 
caTLR4 leads to the induction of antigen-specific CTL 
responses but this is not correlated with a therapeutic 
benefit (unpublished data). This observation points out the 
necessity of adding additional factors to achieve strong 
antitumor immune responses.
Intratumoral delivery of CD40L
The CD40/CD40L interaction was shown to be 
crucial for the induction of potent CTLs [77]. CD40L, 
being expressed on activated CD4+ T cells, was found 
to license the antigen-presenting cells endowing them 
with stronger antigen presentation capacities as well as 
reinforcing the expression of co-stimulatory molecules 
on their surface [78]. Blockade of CD40L decreases the 
number of antigen-specific CTLs, as shown by the group 
of Cornelis J. M. Melief [78]. Based on these findings, 
new therapies were proposed to activate the CD40/CD40L 
pathway. 
Several tumor models with various histological 
origin were transduced in vivo by means of intratumoral 
administration of an adenoviral vector encoding CD40L 
[79–85]. These studies gave satisfying results in most of 
the tested models: intratumoral CD40L-expression led to 
strong antitumor responses and caused tumor regression 
in a dose-dependent manner. In vivo depletion of CD4+ 
and/or CD8+ T cells confirmed involvement of both cell 
types in the generated immune response, although CD8+ 
T cells came out as the major effectors. Moreover, the 
treatment induced T-cell memory, as tumor-free animals 
were protected against re-challenge. The role of CD40/
CD40L stimulation in the induction of anticancer 
immune responses was confirmed using agonistic anti-
CD40 antibodies [85]. It was also demonstrated that 
intratumoral administration of anti-CD40 antibodies was 
effective in licensing strong systemic CTL immunity, 
resulting in eradication of distant tumor nodules without 
side effects. Noteworthy here is the use of a CD40- tumor 
model, which confirms the hypothesis that DCs are the 
most likely targets for the agonistic anti-CD40 antibodies 
[85]. Importantly, distinct mechanisms of action of anti-
CD40 antibodies are described in the murine and human 
setting. Recent studies in mice showed the requirement 
for cross-linking of the Fc-receptor to generate potent 
antigen-presenting cell activation [86]. The clinical 
effects of the anti-human CD40 mAb, CP-870.893, are 
however independent of Fc-receptor cross-linking [86–
89]. Meanwhile, it was shown that expression of CD40L 
on tumor cells facilitates their interaction with DCs 
leading to DC maturation, secretion of cytokines and to 
formation of T-cell dependent antitumor immunity [90]. 
Besides stimulation of CTL responses, agonistic anti-
CD40 antibodies are known for targeting CD40+ tumor 
blood vessels, hereby enhancing tumor neoangiogenesis, 
which could give a pro-tumorigenic result [91, 92]. 
Whether the outcome of anti-CD40 antibody therapy is 
pro- or antitumorigenic will most likely depend on the 
immunogenicity of the tumor. Therefore, it is of interest 
to develop strategies that allow triggering of the CD40 
pathway on antigen-presenting cells, whilst minimize the 
activation of endothelial cells in the tumoral blood vessels. 
The group of Ronald Levy investigated the feasibility of 
combining CD40L therapy with chemotherapy in the 
treatment of murine lymphoma [84]. They showed that 
this combination resulted in a complete tumor regression 
and a long-term survival of mice. Importantly, in this 
combinatorial treatment, the observed effect was due to 
the direct intratumoral injection of the CD40L virus, as 
peritumoral delivery or injection at distant sites did not 
result in a same therapeutic outcome.
Combining TLR agonists with co-stimulatory signals
Based on the promising results obtained with 
TLR- and CD40-triggering, Ahonen et al. [93] showed 
for the first time that the combination of different TLR 
agonists synergized with CD40/CD40L pathway. This 
stimulation resulted in the induction of potent CD8+ T-cell 
expansion that was dependent on type I IFN. B16F10 
tumor-bearing mice were intratumorally injected with a 
plasmid containing soluble CD40L together with different 
TLR agonists [94]. The CD40-activation by itself already 
slowed tumor growth and prolonged survival. Combined 
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with agonists of TLR3 and TLR9 (polyI:C and CpG 
respectively), intratumoral CD40L-administration greatly 
enhanced this therapeutic effect. This was found to be 
associated with a reduction in intratumoral CD11c+ cells 
and an increase in CD8+ T-cell number.
In addition to the combination of TLR and CD40/
CD40L triggering, different co-stimulatory molecules 
were tested to improve T-cell mediated responses. Other 
TNF superfamily members including 4-1BBL, OX-40L, 
CD70 and GITRL were evaluated for their possible use in 
antitumor therapies. These family members were reviewed 
elsewhere [95–99].
To illustrate the potential of co-stimulatory 
molecules, Murphy et al. [100] investigated the use of 
different fusion proteins of co-stimulatory molecules 
(Fc-GITRL, Fc-OX40L, Fc-4-1BBL and CD80-Fc) in a 
murine glioma model. A tumor lysate vaccine was injected 
intradermally to induce primary immune responses 
and followed by systemic administration of different 
co-stimulatory molecules. Solely the combination of 
Fc-OX40L with the vaccine led to 50 % long-term 
survivors, while Fc-GITRL led only to a delayed tumor 
growth. No effects were observed when CD80-Fc and 
Fc-4-1BBL were used. Analysis of T-cell responses after 
administration of the different fusion proteins showed 
a correlation between the survival of the animals and 
the presence of tumor-resident and tumor-draining 
lymph node-resident lymphocytes. Mice treated with 
the vaccine/Fc-OX40L fusion showed an increase in 
CD4+ and CD8+ T-cell proliferation. Re-challenge of the 
long-term survivors led to tumor rejection, indicating 
that immunologic memory against the tumor cells was 
established [100]. 
The use of molecules that block inhibitory signals, 
trigger co-stimulatory signals in combination with the 
stimulation of TLRs was shown by Marabelle et al. [101] 
who injected a TLR9 agonist (CpG nucleotides) together 
with anti-CTLA-4 or anti-OX40 antibodies intratumorally 
to deplete tumor-resident Tregs. This low-dose in situ 
immunotherapy resulted in systemic immune responses 
leading to the eradication of established tumors at distant 
sites and a prolonged survival [101].
In 2008 our group developed a DC vaccination 
platform in which autologous DCs are electroporated 
with a mixture of mRNA molecules encoding for CD40L, 
caTLR4 and CD70, collectively called TriMix [102]. 
This technology was successfully applied in a phase Ia 
clinical trial to treat advanced melanoma patients [103]. 
However, as the tumor-associated antigens are not always 
known/available, we aimed to test the direct intratumoral 
injection of TriMix mRNA (Fig. 2). Upon this treatment, 
tumor-resident DCs were shown to specifically engulf and 
express the mRNA and were reprogrammed to mature 
and migrate towards the tumor-draining lymph nodes 
[104]. This resulted in the induction of tumor-specific 
CTLs in different tumor models. Most importantly, we 
were able to induce an immune response against a neo-
epitope presented by the P815 mastocytoma tumor model. 
Therapeutic experiments showed systemic antitumor 




Intratumoral delivery of cytokines, either as 
proteins or encoded by genes, is a strategy that has 
entered the clinic over a decade ago [105]. This approach 
is characterized by three main requirements: (i) a high 
concentration of the immunomodulatory cytokine inside 
the injected tumors; (ii) the persistence of the cytokine at 
a sufficient concentration to trigger a therapeutic response 
and finally (iii) a low, non-toxic concentration of the 
cytokine outside the tumor nest [106]. Several cytokines 
including IL-2, IL-12, TNF-α, type I IFNs and GM-
Figure 2: mRNA encoding for TriMix as a tool for intratumoral immunization. Upon intratumoral delivery, mRNA encoding 
TriMix (CD40L, caTLR4 and CD70) is taken up by DCs. These tumor-residing DCs pick up tumor antigens, mature upon translation of the 
TriMix mRNA and migrate towards the tumor-draining lymph nodes. Fully matured DCs induce tumor-specific CTLs that in turn migrate 
back to the tumor. Abbreviations: CTL (Cytotoxic T Lymphocytes); DC (Dendritic Cell); TDLN (Tumor-Draining Lymph Nodes).
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CSF possess anticancer potential. Since GM-CSF was 
discussed above, we will focus in this section on the other 
cytokines. 
Intratumoral delivery of IL-2
IL-2 is a glycoprotein that is best known as a growth 
factor for T and NK cells. Upon binding to its receptor, 
IL-2 activates multiple signaling pathways, which promote 
cell survival, proliferation and cytolytic functions [107]. 
Notably, IL-2 also supports the survival and proliferation 
of Tregs [108] and upon prolonged administration to T 
cells it can induce activation-induced cell death [109]. 
Nonetheless, systemic administration of IL-2 was shown 
to exert anticancer potential. This activity, mediated by 
CD8+ T cells, has led to its approval as an anticancer agent 
by the FDA in 1998 after a meta-analysis of 270 patients 
in a total of 8 clinical trials. However, IL-2 systemic 
administration is also associated with adverse events, such 
as pulmonary edema, low blood pressure and low systemic 
vascular resistance as well as hematologic, hepatic and 
renal toxicity [110]. Although these side effects are often 
reversible, it is advisable to deliver IL-2 locally. Gutwald 
et al. [111] were the first to report on the peritumoral 
injection of IL-2 in metastasized melanoma. In contrast to 
its systemic delivery, intratumoral administration of IL-2 
was well tolerated in patients [112]. In the study of Weide 
et al. [113], 72 patients were treated with 3 intratumoral 
injections of IL-2 weekly until clinical regression was 
achieved. This trial demonstrated the long-term benefit of 
intratumoral delivery of IL-2 in stage III patients without 
lymph node involvement and in stage IV patients with soft 
tissue metastasis but without visceral involvement. These 
patients maintained therapeutic responses even when the 
treatment was stopped. Optimized delivery techniques 
could enhance these favorable clinical effects. Zhao et al. 
[114] showed in a preclinical model with dextran PLGA-
PLA microspheres, which continuously releases IL-2, 
the benefit of a single intratumoral IL-2 administration, 
as compared to multiple injections. This highlights the 
importance of sustained local high levels of cytokines 
to achieve therapeutic and immunological responses. 
Alternative strategies have been developed to deliver IL-
2; including adenoviral vectors encoding IL-2 and delivery 
using in vivo electroporation [115]. These strategies have 
shown clinical safety and feasibility but without a clear 
therapeutic benefit for patients [115, 116]. In another 
attempt to circumvent systemic toxicity, IL-2 was fused to 
carcinoembryonic antigen (CEA) targeting moieties [117, 
118]. These targeted IL-2 fusion proteins were shown to 
have tumor localization properties and to inhibit growth 
of CEA expressing tumor cells in transgenic mice. These 
preclinical data have instigated the evaluation of CEA-
targeted IL-2 in a phase I clinical trial [119, 120]. Taken 
together, local delivery of IL-2, as an adjuvant therapy is a 
very attractive and clinically relevant option, especially as 
adverse effects are omitted by local administration.
Intratumoral delivery of IL-12
Although the potential of IL-12 to improve the 
immune stimulating capacity of DCs was discussed 
above; the following section will focus on its antitumor 
characteristics. Systemic administration of IL-12 was 
shown to promote antitumor immunity, counteract 
angiogenesis and tumor cell dissemination. This antitumor 
outcome is attributed to the direct inhibitory effect of IL-
12 on the induction of metalloproteases, the increased 
lyses of endothelial cells as well as to its indirect effect 
on the induction of IFN-γ. The latter leads to a decreased 
expression of VEGF and integrin αVβ3, and an increased 
expression of the anti-angiogenic factors Mig-2 (CXCL9) 
and IP-10 (CXCL10) [121]. Moreover, IFN-γ enhances the 
expression of MHC molecules on DCs and of the TH1-
polarizing factor T-bet in CD4+ T cells [122]. It was shown 
in distinct comparative studies that IL-12 is one of the 
most effective cytokines to eradicate experimental tumors, 
to prevent metastases and to induce long-term antitumor 
immunity [123, 124]. However, systemic administration of 
IL-12 is also associated with profound toxicity, including 
increased serum aminotransferases, stomatitis, leucopenia, 
thrombocytopenia and anemia [125, 126]. Different 
strategies have been exploited to deliver the IL-12 gene 
to the tumor environment, including IL-12 encoding 
plasmid DNA [124, 127–132] or viral vectors [133–136]. 
Alternative approaches have been developed to deliver the 
IL-12 protein such as: particles that mediate a slow IL-
12 release [137, 138] or IL-12-secreting tumor-specific T 
cells [139, 140]. It became clear from these studies that 
intratumoral delivery of IL-12 can exert antitumor effects 
resulting in the regression of (metastatic) tumors in various 
models, amongst which melanoma, adenocarcinoma, renal 
cell, colorectal and hepatocellular carcinoma. It has been 
demonstrated that the antitumor effects of IL-12 within the 
tumor depend on CD4+ and CD8+ T cells, NK cells and/or 
NKT cells [141–143]. Additionally, IL-12 can functionally 
reprogram myeloid cells, such as MDSCs [123, 136, 144, 
145]. Kerkar et al. showed that these cells express high 
levels of the functional IL-12 receptor-β2 subunit and 
upon IL-12 sensing they lose their suppressive activity, 
and can even obtain T-cell stimulating abilities [146]. 
These pre-clinical studies highlight that local delivery of 
IL-12 is an attractive approach as it can exert antitumor 
effects with little to no toxicity. The latter is confirmed 
by the clinical responses observed in patients with renal 
cell carcinoma, melanoma and peritoneal metastasis from 
ovarian cancer upon intratumoral IL-12 treatment [147–
151]. Despite the encouraging results described in these 
studies, not all clinical trials have been successful. Triozzi 
et al. [152] were unable to demonstrate clinical benefit of 
intratumoral administration of canarypox-based vectors 
harboring IL-12 in a phase I clinical trial in metastatic 
melanoma. In spite of some setbacks, the relevance of 
IL-12 as an anticancer cytokine is undeniable and its 
importance in cancer immunotherapy continues to grow. 
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Intratumoral delivery of TNF-α
Another potential treatment target, which gained 
attention thanks to the pioneering work of William Coley, 
is TNF-α. This cytokine is produced by various cell 
types upon triggering of TLR4 by LPS [153]. Different 
strategies have been developed to enrich the tumor 
environment with TNF-α, such as delivery of the TNF-α 
protein directly [154] or with microspheres [155, 156], 
delivery of the TNF-α gene using adenoviral vectors [157–
159] or plasmid DNA [157]. Treatment with TNF-α was 
shown to (i) induce NK and T cell-mediated immunity, 
(ii) to reduce the Treg population and (iii) to decrease 
tumor cell survival [155, 157, 159, 160]. These antitumor 
effects could be further enhanced by combining TNF-α 
with other cytokines such as IL-12 [155, 160] or classical 
therapies, like radiation therapy [158] or chemotherapy 
[159], making intratumoral delivery of TNF-α an attractive 
adjuvant treatment.
Intratumoral delivery of type I IFNs
Another cytokine that has been studied in the 
adjuvant context is IFN-α; a member of a gene family 
consisting of 13 members. Over half a century ago, it 
was discovered that this cytokine interferes with viral 
infections. A decade later, type I IFNs were shown to 
exert antitumor functions, such as tumor cell growth 
suppression and immune stimulation [161, 162]. Notably, 
IFN-α was approved by the FDA for the treatment of 
several cancers, including hairy cell leukemia, chronic 
myeloid leukemia, melanoma, renal cancer, myeloma, 
lymphomas and Kaposi’s sarcoma. Although promising 
results were obtained in hematopoietic cancers, little 
success was achieved in solid tumors using systemic 
administration of IFN-α as a single agent [163]. Moreover, 
its systemic delivery often results in severe side effects, 
such as autoimmune and inflammatory symptoms and 
direct tissue toxicity [164]. IFN-β has also made its 
way to the clinic; for the treatment of multiple sclerosis, 
hepatitis B and to a lesser extent cancer [165–167]. Lower 
doses of IFN-α and IFN-β were suggested for adjuvant 
therapy, as this could reduce the risk of developing 
secondary cancers [168–170]. However, a concern with 
regard to the clinical use of type I IFNs is its impaired 
signaling. The exact mechanism is not clear yet; different 
factors such as immunosuppressive cytokines found in 
the tumor environment could be responsible. Critchley-
Thorne et al. showed that both IFN-α and IFN-γ signaling 
was reduced in distinct lymphocyte subsets from patients 
with breast cancer, melanoma and gastrointestinal cancer 
[171]. However, because type I IFNs are promising 
therapeutic agents with a limitation on their systemic 
use due to toxicity, studies on the intralesional delivery 
of type I IFNs have been conducted. The local injection 
of recombinant IFNs [172], plasmid DNA encoding them 
[173], compounds eliciting endogenous release [62, 67] or 
the systemic delivery of tumor-specific antibodies coupled 
to type I IFNs [174, 175] were evaluated. Comparative 
pre-clinical studies showed the superiority of intratumoral 
over intravenous delivery of type I IFNs in terms of 
survival and toxicity [62, 176, 177]. 
To circumvent the toxicity issues Xuan et al. 
[175] created a fusokine composed of rituximab (anti-
CD20) fused to IFN-α. This fusokine was administrated 
intravenously and overcame the toxicity issues linked 
with systemic delivery of IFN-α alone. In line with this 
study, Xuanming et al. [174] developed similar fusokines 
consisting of IFN-β and the antibody against Neu or EGFR 
and showed that therapy resistance could be overcome. 
This finding is of great importance as antibody resistance 
is a major issue for antibody-based cancer therapies. 
This approach focuses on the reactivation of innate and 
adaptive immune cells in the tumor microenvironment to 
overcome antibody-based resistance. Of note, both studies 
demonstrated that it is feasible to deliver an immune 
modulating molecule systemically and still achieve its 
local effects due to the tumor-targeting antibody that was 
fused to it. 
The local delivery has the advantage of achieving 
high concentrations with minimal toxicity. This is 
important as many effects are exerted only at higher IFN 
concentrations [178, 179]. For instance, IL-6 secretion by 
DCs triggered with type I IFNs has been shown to be dose 
dependent [178]. The local increase of type I IFNs also 
diminishes the suppressive function of MDSCs, whilst 
enhancing the immune stimulating ability of DCs and 
the cytolytic function of NK and CD8+ T cells. Another 
advantage of type I IFNs is their ability to act on tumor 
cells by decreasing their proliferative rate as well as their 
viability [180]. In addition, tumor cells up-regulate several 
surface markers upon triggering of the IFN-α receptor 
(IFNAR1 or 2). Some of these molecules like MHC I 
are thought to support the antitumor immune response, 
whilst others are inhibitory molecules like the ligand 
of programmed death 1 receptor (PD-L1), which upon 
interaction with its receptor PD-1, expressed on effector 
T cells, impairs T cell responses. Given this combined 
effects, it is likely that type I IFNs will not be used as a 
monotherapy. In this regard, pre-clinical studies showed 
that intratumoral treatment with type I IFNs accompanied 
by PD-1 targeting leads to local tumor suppression [174, 
181]. Moreover, combining of the intravenous antibody-
IFN-β fusokines with PD-L1 blockade lead to complete 
eradication of tumors. In summary, the data described 
above suggests diverse options for the application of 
cytokines in the treatment of various tumors. 
Soluble receptors that capture immunosuppressive 
cytokines
The tumor and its microenvironment represent 
a potent source of anti-inflammatory and suppressive 
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factors, which cause defects in the differentiation and 
maturation of immune cells, resulting in the generation of 
tolerogenic DCs, Tregs and MDSCs. These cells in turn 
can suppress the activity of effector cells in the tumor 
microenvironment by the secretion of soluble molecules 
such as IL-10, IL-35 and TGF-β [182]. Therefore, an 
indirect way to inhibit these negative regulators and 
enhance the activity of effector cells is by blocking 
suppressive cytokines. 
Intratumoral neutralization of TGF-β
TGF-β is the most pleiotropic and influential 
factor in the tumor environment as it not only affects 
most immune cells but also plays a key role in tissue 
regeneration and angiogenesis. This growth factor 
is known to inhibit proliferation, differentiation and 
maturation of T and B cells as well as to suppress the 
cytotoxicity of NK cells against tumor cells. Furthermore, 
it decreases the capacity of antigen-presenting cells to 
activate effector T cells and it promotes the generation and 
expansion of Tregs through the conversion of immature 
myeloid DCs. Additionally, TGF-β promotes metastasis 
and formation of tumor stroma [183]. Noteworthy, TGF-β 
has also been proposed to have a tumor-suppressing 
role in cancer. In a mammary tumor model, TGF-β was 
shown to function both as a tumor promoter and tumor 
suppressor [184]. In osteosarcoma, TGF-β also regulates 
metastatic cascades as well as normal bone remodeling 
and formation. Nonetheless, pre-clinical models showed 
that blockade of TGF-β was effective to treat and prevent 
bone metastases, and to increase the bone mass [185]. The 
therapeutic potential of this strategy was also shown in 
several mouse tumor models, amongst which renal cell 
cancer [186], melanoma [187], hepatocellular carcinoma 
[188], and glioma [189]. Therefore, approaches that inhibit 
TGF-β are under development. These include neutralizing 
antibodies, soluble receptors, TGF-β-binding proteins, 
small-molecule inhibitors, receptor kinase antagonistic 
drugs and antisense reagents [190, 191]. TGF-β blockade 
in combination with other treatments has been tested in 
mice for its immune stimulatory capacity. Intraperitoneal 
injection of a TGF-β neutralizing antibody showed 
enhanced cytarabine-induced apoptosis in acute myeloid 
leukemia cells and improved delivery and efficacy of a 
chemotherapeutic in two mammary carcinoma models 
[192, 193]. The latter was explained by enhanced 
intratumoral penetration of the chemotherapeutic leading 
to a better control of tumor growth. The efficacy of 
T-cell receptor gene therapy was also greatly augmented 
in prostate tumor bearing mice upon injection of T-cell 
receptor-modified CD8+ T cells expressing a dominant-
negative TGF-β receptor II [194]. Numerous in vitro 
studies also provide rationale in favor of blocking 
TGF-β signaling in human tumors. For example, the 
introduction of dominant-negative TGF-β receptors into 
metastatic breast cancer cells, inhibited their epithelial-to-
mesenchymal transition, motility, invasiveness, survival 
and metastases [195]. This was further supported by a 
study in which inhibition of TGF-β signaling in splenic 
CD8+ T cells isolated from F5 mice promoted the 
generation of CD62Lhigh/CD44high central memory CD8+ 
T cells. These data were confirmed in human peripheral 
blood mononuclear cells [196].
Importantly, the specific blockage of TGF-β, via 
intratumoral delivery of triple immunotherapy, consisting 
of anti-CD25, anti-TGF-β and anti-CTLA-4 monoclonal 
antibodies, in the treatment of mesothelioma, was shown 
to lead to the favorable therapeutic outcome [197]. 
Combination of these three agents led to complete tumor 
eradication and protection from re-challenge. The timing 
of intratumoral administration did not impair the outcome, 
as long as the three components were administered 
together. These data together with previous findings are in 
favor to target TGF-β locally.
Intratumoral neutralization of IL-10
IL-10 has also been considered as a target to 
enhance antitumor immunity. It affects antigen-presenting 
cells directly by down-regulating MHC and co-stimulatory 
molecules. Additionally, it diminishes the expression of 
TH1 cytokines like IFN-γ, while it induces Tregs [198]. 
On that account, intravenous injection of murine IL-10 
receptor blocking antibodies or oligonucleotide aptamers 
resulted in the inhibition of tumor growth in a colorectal 
cancer model [199]. When subcutaneously administered, 
anti-IL-10 receptor antibodies also showed a protective 
effect upon subsequent melanoma or anaplastic large cell 
lymphoma challenge. Moreover, when combined with 
peptide-pulsed DCs, complete protection was achieved. 
This was attributed to an increase of CD4+ granzyme+ T 
cells and a decrease in Tregs [200]. Co-administration 
of anti-IL-10 antibodies with LPS, induced improved 
immune responses. Intraperitoneal delivery of anti-
IL-10 receptor antibodies in combination with BCG 
was effective for the treatment of bladder cancer [201]. 
Besides its tolerogenic properties, IL-10 also exerts 
anti-angiogenic effects with both tumor promoting and 
inhibiting results. It was concluded that IL-10 ablation 
promotes tumor development, growth and metastasis as 
tumor growth in IL-10 knock out mice was associated 
with an increased level of MDSCs and Tregs in both the 
tumor environment and in the tumor-draining lymph nodes 
[202]. Therefore, caution should be taken with anti-IL-10 
treatment during pre-clinical evaluation. 
Of note, IL-19, a member of the IL-10 family, which 
also contributes to a range of diseases, was recently linked 
to the progression of cancer [203]. In breast cancer for 
example, this cytokine is correlated with an increase of 
mitotic figures, advanced tumor stage, higher metastasis, 
and poor survival. IL-19 has an autocrine effect on 
breast cancer cells by directly promoting proliferation 
and migration of tumor cells while indirectly providing 
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a microenvironment for tumor progression. This suggests 
a prognostic value of IL-19 and a possible therapeutic 
potential of its antagonists.
Intratumoral neutralization of IL-35
Apart from TGF-β and IL-10, expression of the 
Treg-associated cytokine IL-35 has been demonstrated 
in the tumor environment. It appears to promote tumor 
growth by enhancing myeloid cell accumulation and 
angiogenesis, hereby weakening spontaneous CTL 
responses [204]. Although it has been shown that IL-35 
is mainly produced by Tregs, gene expression analysis 
has revealed that IL-35 has likely a wider distribution, 
including expression by human cancer cells such as 
melanoma. The presence of IL-35 seemed to correlate 
with the severity of the disease and the clinical stage of 
the tumor in colorectal cancer [205]. Interestingly, it was 
shown for human prostate cancer that Tregs mediate their 
effects via CTLA-4 and IL-35 while IL-10 or TGF-β 
blockade does not abrogate their suppressive activity 
[206]. It has been also observed that IL-35 over expression 
increases apoptosis sensitivity and suppresses cell growth 
in human cancer cells [207]. Likewise as with IL-10, 
caution is needed when evaluating anti-IL-35 treatments 
for cancer.
In conclusion, several immunosuppressive cytokines 
are present in the tumor microenvironment; in depth 
understanding of their pro- and antitumorigenic roles, 
which depend on the species, tumor type and tissue as 
well as its inflammatory status is crucial for the success of 
therapy involving these molecules.
Fusokines: combining the best of two worlds 
Intratumoral delivery of cytokines or blockade 
of immunosuppressive cytokines showed promising 
immunological and clinical benefit, however not in all 
patients. Combination of immune modulators could help 
to achieve the required therapeutic potency, especially 
given that the resistance to a certain immune modulator 
can occur. Since we theoretically could combine an infinite 
amount of cytokines and blocking agents, an important 
question that arises is: ‘Which combination should be 
used for which cancer type’? Screening of the patients for 
the presence of inhibitory mechanisms, tumor cytokines 
or genes encoding them would serve for the proper design 
of the treatment. 
Penafuerte et al. developed a fusokine by combining 
IL-2 and the ectodomain of the TGF-β receptor II. When 
delivered intratumorally, this fusokine, named FIST, 
acts as a “sword and shield” strategy by trapping locally 
produced TGF-β and stimulating lymphocytes with IL-2. 
FIST was shown to recruit NK cells, NKT cells, CD8+ T 
cells and B cells to the tumor. In addition, the lymphocytes 
were shown to secrete higher levels of IFN-γ upon FIST 
stimulation. 
Inspired by these findings as well as the observation 
that IFN-β could be combined with a TGF-β signaling 
agonist [208], we generated mRNA encoding for 
a fusokine named Fβ2, consisting of IFN-β and the 
ectodomain of the TGF-β receptor II (Fig. 3) [181]. The 
Fβ2 fusokine reduced the suppressive capacity of MDSCs 
and increased the stimulatory capacity of DCs. Moreover, 
CD8+ CTLs showed enhanced tumor cell recognition upon 
exposure of tumor cells to the fusokine. In tumor bearing 
mice, depletion of CD8+ T cells abrogated the antitumor 
effect. This approach offers potent immune stimulation 
devoid of TGF-β mediated suppressive effects. Similarly 
to Xuanming et al. [174] we [181] obtained improved 
therapeutic responses via specific targeting of the type I 
IFN induced PD-L1 up-regulation.
These studies highlight the complexity of tumors 
and their environment and show that immunotherapeutics 
can have diverse effects, resulting in a delicate balance 
between immune stimulation and immune inhibition. 
Tipping this balance to immune stimulation in order to 
have effective antitumor responses will most likely be 
obtained through combination of multiple therapies (Fig. 
4). In this regard, immune checkpoints have increasingly 
gained attention, as these are believed to majorly impact 
on immune-mediated tumor rejection.
Immune checkpoint blockade
The ability of cancer cells to suppress antitumor 
T-cell activity in their microenvironment was pinpointed 
by Hanahan and Weinberg as one of the hallmarks 
of cancer progression [209]. Multiple inhibitory 
ligands and receptors expressed by tumor cells, tumor-
infiltrating myeloid cells and lymphocytes can account 
for this anticancer activity. T-cell activation requires 
antigen recognition by the T-cell receptor as well as 
complementary signals, coming from co-stimulatory 
molecules and cytokines. The opposite, T-cell ignorance, 
is mediated by inhibitory checkpoints that hamper proper 
activation. These inhibitory checkpoints are known to 
down-regulate effective antitumor immunity. Therefore 
immune checkpoints have gained increasing attention as 
novel therapeutic targets. In 2013, the editors of ‘Science’ 
proclaimed cancer immunotherapy, more specifically 
the blockade of inhibitory immune checkpoints, as 
‘Breakthrough of the year’ [210]. The relevance of 
targeting immune checkpoint molecules is highlighted by 
the numerous reviews that have recently been published 
[211–219].
Antibodies against CTLA-4 and members of 
the PD-1/PD-L1 pathway have been extensively and 
successfully studied in both the pre-clinical and clinical 
setting. However, there are many other molecules that are 
able to down-regulate T-cell functions, amongst which 
T-cell immunoglobulin and mucin domain-containing 
protein-3 (Tim-3) and Lymphocyte activation gene-3 
Oncotarget1370www.impactjournals.com/oncotarget
(Lag-3). Therefore, it is not surprising that monoclonal 
antibodies against Tim-3 and Lag-3 are also under 
development [220–222].
Of the monoclonal antibodies that were generated 
only those directed against CTLA-4 have been studied for 
local delivery. CTLA-4 is a regulator of early stage T-cell 
activation in response to antigen; it puts a brake on T cells, 
preventing them from launching uncontrolled immune 
attacks [223]. CTLA-4 is a homolog of CD28 and plays an 
important role in the development of peripheral tolerance 
to self-proteins [224, 225]. The main ligands for CTLA-
4 are B7-1 (CD80) and B7-2 (CD86), which transmit an 
inhibitory signal to CTLA-4 expressing T cells. Diverse 
anti-CTLA-4 monoclonal antibodies are developed of 
which ipilimumab, a human IgG1 anti-CTLA-4 antibody, 
and tremelimumab, an IgG2 anti-CTLA-4 antibody, are 
best known. Currently, ipilimumab is broadly used in 
clinical trials and already demonstrated the potential to 
improve the overall survival of cancer patients, either as a 
single agent or in combination with other therapies [226–
231]. Treatment with tremelimumab was shown to enhance 
the diversity of the T-cell receptor repertoire and increase 
the total T-cell number, without an expansion of specific 
clones [232]. To have a better insight in the clinical benefit 
for anti-CTLA-4 treatment, the tumor genetic landscape 
was scrutinized. Interestingly, it was shown that patients, 
Figure 4: Combination therapy: the way forward. The combination of cytotoxic pharmaceutics is a standard strategy in clinical 
oncology to increase clinical responses. A similar paradigm has emerged in cancer immunotherapy. It is believed that strategies that aim at 
inducing tumor-specific T cells should be combined with strategies that counteract mechanisms devised by the tumor and its environment 
to down-regulate T cell-mediated tumor cell rejection. We contend that smart combinations of the strategies discussed in this review, in 
particular immunization and immunomodulation, are key to the eradication of some of the currently difficult to treat tumors.
Figure 3: mRNA encoding for Fβ2 as a tool for intratumoral immunomodulation. mRNA encoding Fβ2, a fusokine consisting 
of IFN-β fused to the ectodomain of the TGF-β receptor II, is taken up by tumor-residing DCs. These DCs serve as factories to produce 
therapeutic amounts of the fusokine. This fusokine creates a CTL-friendly environment and as such contributes to antitumor immunity. 
Abbreviations: CTL (Cytotoxic T Lymphocytes); DC (Dendritic Cell); IFN-β (Interferon-β); TGF-β (Transforming-Growth Factor-β).
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which tumors possessed certain neoepitopes displayed a 
prolonged benefit from the anti-CTLA-4 blockade [233, 
234]. The effects of the therapy are not only related to the 
effector T-cell function but also to the interference with 
Tregs. In this regard, it has recently been shown in mice 
that treatment with anti-CTLA-4 monoclonal antibodies 
might deplete Tregs in the tumor microenvironment [235]. 
However, immune-related auto-reactivity and toxicity 
have been reported and can be explained by the fact that 
CTLA-4 plays a critical role as a negative regulator of 
T-cell activation [214]. Moreover, CTLA-4 knock out mice 
develop autoimmune disease which is lethal at the age of 3 
to 5 weeks. Nevertheless, Fransen et al. described efficient 
systemic activation of tumor-specific T cells by the peri-
tumoral administration of CTLA-4-blocking antibodies 
in the lipid-based adjuvant montanide [213, 236]. Using 
a slow-release formulation they could drastically reduce 
side effects and decrease the risk of autoimmune reactions 
without losing the systemic effect. Similarly, Marabelle et 
al. [101] co-injected intratumorally ODNs, anti-CTLA-4 
and anti-OX40 antibodies, and achieved superior effects 
to those obtained by the systemic administration of a 
100-fold higher dose of anti-CTLA-4 antibodies. In this 
approach, tumor-residing Tregs were depleted, which 
boosted the immune responses. Both of these pre-clinical 
studies highlighted the value of the intratumoral approach 
and showed that local delivery of anti-CTLA-4 exerts 
similar antitumor responses to its systemic administration.
GENERAL CONCLUSIONS 
A great effort was made to develop treatment 
modalities that directly target the tumor. As outlined 
throughout the review, intratumoral administration of 
immunotherapies holds several advantages and only 
a few disadvantages when compared to their systemic 
delivery. The pro’s and con’s of using the tumor as a site 
of immunotherapy are summarized in table 1. 
Modulation of the tumor microenvironment appears 
as an elegant way to generate therapeutic responses. 
However supplementation of a single factor, except for 
some cases, is often not resulting in beneficial outcome. 
Therefore, it is essential to combine different stimulatory 
factors with proper alleviation of inhibitory mechanisms. 
It still needs to be addressed whether a golden standard 
mix, which suits most of the tumors or rather tumor-
specific mix would offer greater therapeutic benefit. In this 
regard, clinical data from ongoing and future studies will 
provide valuable information. 
The evolution of cancer research clearly showed that 
this disease is highly potent in countering drugs aiming at 
destroying it. Therefore, a certain immune boost is needed 
to overcome the development of escape mechanisms 
and to generate strong memory responses. In figure 4 
we propose the components of an ideal mix that should 
consist of 1) proper DC maturation and T-cell stimulating 
signals, 2) blockade of inhibitory immune checkpoints 
and 3) neutralizers of immunosuppressive cytokines. We 
believe that the combinatorial therapies are the future of 
cancer treatment and that they will bring a clear benefit for 
the patients in the coming years.
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Table 1: Advantages and disadvantages of using the tumor as a site of immunotherapy.
Advantages Disadvantages
No need to identify antigens or HLA for 
immunization purposes.
Tumors are not always accessible.
Site of manipulation is the site of action for the 
effector cells.
Ability to manipulate the tumor environment.
Intratumoral therapy has to proceed surgical removal 
of the tumor, which entails a delay of this classical 
therapy.
Local therapy can result in systemic responses.
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